COMPANY
Cellerant Therapeutics
Cellerant Therapeutics is listed on ClinicalTrials.gov as the lead sponsor of 3 studies; the most recently updated is “Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia” (Phase 2, completed), in Acute Myeloid Leukemia, Neutropenia, Infection. Cellerant Therapeutics has received NIH funding, most recently in fiscal 2019 for the project “Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation”. From public records Source · Oct 12, 2026
Timeline
- Trial start Phase 2: Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia source ↗
- Trial start Phase 1/Phase 2: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia source ↗
- Trial start Phase 1: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy source ↗
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT02282215 | Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia | Phase 2 | Completed | 2014-12 | Sep 22, 2017 (actual) |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | Phase 1/Phase 2 | Completed | 2011-03 | 2014-11 (actual) |
| NCT00891137 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | Phase 1 | Completed | 2009-04 | 2014-06 (actual) |